psilocybin + ketamine + MDMA

This is a preclinical fixed-dose combination drug being developed by **Shanti Therapeutics** (a subsidiary of **Xtacy Therapeutics**) in partnership with the **Swinburne Institute of Technology**. The therapeutic combines three psychoactive small molecules: **psilocybin**, **ketamine**, and **MDMA** (3,4-methylenedioxymethamphetamine). The combination is designed to leverage synergistic effects across multiple neurotransmitter systems: psilocybin acts as a **5-HT2A receptor agonist**, ketamine as an **NMDA receptor antagonist**, and MDMA as a **monoamine transporter modulator** (acting on SERT, DAT, and NET). The primary therapeutic goal is to provide enhanced antidepressant and analgesic effects for the treatment of **chronic pain** and **depression**, specifically aiming to reduce the psychosocial component of pain. Shanti Therapeutics is positioning itself as a first mover in the Australian psychedelic space, holding licenses for the supply of these substances and planning a telehealth clinic for their administration.

Other names

psilocybin + ketamine + 3,4-methylenedioxymethamphetamine